As a CRO service provider, Creative Biolabs focuses on developing novel therapeutic antibody programs, with the help of our partners, to fight cancer. We guarantee every step of the program is original, unique, and to your satisfaction. Our team will try our best to move the progress forward. We believe the high degree of collaboration will help with project developments, compared with the current CRO service pattern. This anti-CD48 monoclonal antibody program aims to develop therapeutic mAb against CD48 expressed on tumor cells.
Learn more about Next-IO™ Anti-CD48 Monoclonal Antibody Program: https://www.creative-biolabs.com/immuno-oncology/anti-cd48-monoclonal-antibody-program.htm